Paradigm Biopharmaceuticals (ASX:PAR) received centralized Human Research Ethics Committee approval in Australia for its pivotal PARA_OA_012 phase three clinical trial, which will study the safety and efficacy of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis, according to a Monday Australian bourse filing.
It said the recruitment of the first subject for the trial is on target and first participant dosing is expected in the second quarter, the filing said.
The approval allows the trial to proceed across multiple key clinical trial sites in Australia, the filing said.
The first trial sites to be activated are expected to be located in Victoria.
The firm's shares rose 2% in early trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.